Vietnam has become the 39th nation cleared for global exports of the vaccines it makes, joining an increasingly crowded field of local champions to multinational heavyweights. The World Health Organization gave that clearance recently for a country that expects to be a leading producer within the next 20 to 30 years.
This past season's flu vaccines posted one of the worst efficacy rates in recent memory. That's partly because the viral strains they contained weren't the ones that ended up circulating. But on top of that, GlaxoSmithKline has uncovered some other effectiveness problems of its own--and now it's recalling a quadrivalent jab in a move that affects 1.7 million doses.
As it beefs up its vaccines business, Pfizer's looking to bolster revenue from the top-selling Prevenar family of shots. But on that front, it's come up against a roadblock in China--and so it's shutting down its vaccines marketing there.
Two gatherings in Kuala Lumpur, Malaysia this week, although held separately, came close, but not quite, to bringing together the twin issues of vaccines and the practice of halal by Muslims who comprise a third of Asia's population. Apparently, neither of the two primary gatherings had the concerns of the other on its agenda.
The African ape population has played a key role in the enduring threat posed by ebolavirus. Now a group of investigators say they have some new animal data that suggest a CMV-based vaccine could spark the spread of a protective "disseminating" virus that may prevent the threat in the first place.
China's Sinovac Biotech said it is close to receiving marketing approval for its vaccine for preventing the EV71 virus responsible for hand, foot and mouth disease, a common ailment in Asia that often is fatal.
GlaxoSmithKline and Novartis have finally closed the multibillion-dollar asset swap that's sending GSK's oncology portfolio to Switzerland in exchange for most of the latter's vaccines unit. Now, all eyes will be on the British pharma giant, who industry watchers agree has more to prove after exiting the fast-growing cancer field.
Indonesia has long been active in providing vaccines to other developing countries, but now finds itself in a bind and turning to its state-owned and century-old pharmaceutical company, Bio Farma, to solve the nation's own growing need for vaccines.
The board of directors at GlaxoSmithKline voted to approve the last phase of a three-part deal with Novartis, transferring GSK's cancer drug portfolio to Novartis Healthcare Pvt, its Indian arm. Distribution rights were ceded in exchange for acquiring the Swiss-based company's vaccines portfolio.
GlaxoSmithKline's job-chopping ax has struck Hamilton, MT, where 27 vaccine researchers will pack up this year. The pharma giant plans to centralize its R&D efforts in one location, but where that will be hasn't yet been decided, company spokeswoman Melinda Stubbee told local paper Missoulian.